Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06573411 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary and study completion dates: Oct 30, 2025 to Oct 30, 2026
    • Primary endpoint revised
    • Enrollment target: 88 to 116
    • Interventions: ACEI/ARB+ Placebo (Drug), ACEI/ARB+ finerenone (Drug) to ACEI/ARB (Drug), ACEI/ARB+ finerenone (Drug)
    • Study description shortened, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.
Trial Details
NCT Number NCT06573411
Lead Sponsor First Affiliated Hospital, Sun Yat-Sen University
Conditions
(from sponsor)		 Primary Membranous Nephropathy
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov